Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03340506 | Dabrafenib and/or Trametinib Rollover Study | recruiting | Phase 4 | 100 | Novartis PharmaceuticalsINDUSTRY | 14 | Sep 23, 2026 | clinicaltrials |
| NCT04296305 | Effect of Opioid Infusion Rate on Abuse Liability Potential of Intravenous Hydromorphone for Cancer Pain | active not recruiting | Phase 4 | 84 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07405086 |
| Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study |
| recruiting |
| Phase 4 |
| 160 |
| OHSU Knight Cancer InstituteOTHER |
| 1 |
| Jun 12, 2026 |
| clinicaltrials |
| NCT07590648 | Early Discontinuation of Antibiotics in Paediatric High-risk Febrile Neutropenia(E-STOP2) | not yet recruiting | Phase 4 | 136 | Hospital Universitari Vall d'Hebron Research InstituteOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT05203172 | The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials | recruiting | Phase 4 | 46 | PfizerINDUSTRY | 17 | Apr 7, 2026 | clinicaltrials |
| NCT05525767 | Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer | recruiting | Phase 4 | 75 | Hebei Medical University Fourth HospitalOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT03229200 | Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. | active not recruiting | Phase 4 | 297 | Pharmacyclics Switzerland GmbHINDUSTRY | 17 | Oct 30, 2025 | clinicaltrials |
| NCT06824792 | Optimal Standard Treatment Selection for Solid Tumor Patients by Biologically-informed Multi-agent System(SINGULARITY) | not yet recruiting | Phase 4 | 3,000 | NING LIOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT06408688 | Safety and Modulation of Adaptive Immunity by Iscador® Qu Viscum Album Extract in Patients With Advanced, Recurrent or Metastatic Cancers Treated With Immune Checkpoint Inhibitors(ISCA-CHECK) | recruiting | Phase 4 | 100 | University Hospital, Basel, SwitzerlandOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT04475705 | Propofol vs Sevo for Paediatric Tumor Surgery | recruiting | Phase 4 | 100 | Hong Kong Children's HospitalOTHER | 1 | Mar 16, 2022 | clinicaltrials |
Data updated 4 days agoSource updated Sep 23, 2026source: clinicaltrials